忍者ブログ

ニュースリリースのリリースコンテナ第一倉庫

ニュースサイトなど宛てに広く配信された、ニュースリリース(プレスリリース)、 開示情報、IPO企業情報の備忘録。 大手サイトが順次削除するリリースバックナンバーも、蓄積・無料公開していきます。 ※リリース文中の固有名詞は、発表社等の商標、登録商標です。 ※リリース文はニュースサイト等マスコミ向けに広く公開されたものですが、著作権は発表社に帰属しています。

2025'03.17.Mon
×

[PR]上記の広告は3ヶ月以上新規記事投稿のないブログに表示されています。新しい記事を書く事で広告が消えます。

2007'02.10.Sat
Sinovac Biotech Ltd. Announces First Sales of its Seasonal Influenza Vaccine, Anflu(TM)
September 27, 2006

    BEIJING, Sept. 27 /Xinhua-PRNewswire/ -- Sinovac
Biotech Ltd. (AMEX: SVA) announced today that the third
product of the Company, seasonal influenza vaccine, is
successfully released for sale by National Institute for
the Control of Pharmaceutical and Biological Products
("NICPBP").  On the same day, the first bunch of
purchase orders is signed with several customers.  These
purchase orders represent a major step for the Company as
its third vaccine product begins sales in China.  And it is
expected to be another major source to generate sales
revenue for the Company. 

    Sinovac's VP of Marketing and Sales commented, "We
expect Chinese flu vaccine market to bear a high growth rate
when people's awareness of health is enhanced and their
disposable income is increased.  This is the third product
of Sinovac. Our sales team is encouraged. And they are
confident to successfully bring this product to the Chinese
market. " 

    About Sinovac 

    Sinovac Biotech Ltd. is a China-based biopharmaceutical
company that focuses on the research, development,
manufacture and commercialization of vaccines that protect
against human infectious diseases. Sinovac's vaccines
include Healive(TM) (hepatitis A), Bilive(TM) (combined
hepatitis A and B) and Anflu(TM) (influenza).  Sinovac is
currently developing human vaccines against the H5N1 strain
of pandemic influenza, Japanese encephalitis and SARS. 

    Additional information about Sinovac is available on
its website, http://www.sinovac.com .  To be added to our
distribution list, please email: info@sinovac.com . 

    Safe Harbor Statement 

    This announcement contains forward-looking statements.
These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform
Act of 1995.  These forward-looking statements can be
identified by words or phrases such as "will,"
"expects," "anticipates,"
"future," "intends," "plans,"
"believes," "estimates" and similar
statements. Among other things, the business outlook and
quotations from management in this press release contain
forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's
beliefs and expectations, are forward-looking statements. 
Forward-looking statements involve inherent risks and
uncertainties.  A number of important factors could cause
actual results to differ materially from those contained in
any forward-looking statement. Sinovac does not undertake
any obligation to update any forward-looking statement,
except as required under applicable law. 

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com 

SOURCE  Sinovac Biotech Ltd.
PR
Post your Comment
Name:
Title:
Mail:
URL:
Color:
Comment:
pass: emoji:Vodafone絵文字 i-mode絵文字 Ezweb絵文字
trackback
この記事のトラックバックURL:
[7645] [7644] [7643] [7642] [7641] [7640] [7639] [7638] [7637] [7636] [7635
«  BackHOME : Next »
広告
ブログ内検索
カウンター

忍者ブログ[PR]